Key result
SH2B1 knockdown via siRNA mitigated pressure overload-induced cardiac hypertrophy and dysfunction by reducing cardiac glucose metabolism through the PI3K/AKT pathway.
Why the study?
The effect and mechanism of SH2B1 on cardiac glucose metabolism during pressure overload-induced cardiac hypertrophy and dysfunction remained to be determined.
Does SH2B1 knockdown improve cardiac hypertrophy and dysfunction in a pressure overload model?
Does SH2B1 knockdown improve cardiac hypertrophy and dysfunction in a pressure overload model?
SH2B1 knockdown mitigates pressure overload-induced cardiac hypertrophy and dysfunction by reducing cardiac glucose metabolism via the PI3K/AKT pathway.
No immediate clinical implications; leaves open SH2B1 as a hypothesis-generating metabolic target in hypertrophy.
This study mainly explored the effect and mechanism of Src homology 2 (SH2) B adaptor protein 1 (SH2B1) on cardiac glucose metabolism during pressure overload-induced cardiac hypertrophy and dysfunction. A pressure-overloaded cardiac hypertrophy model was constructed, and SH2B1-siRNA was injected through the tail vein. Haematoxylin and eosin (H&E) staining was used to detect myocardial morphology. ANP, BNP, β-MHC and the diameter of myocardial fibres were quantitatively measured to evaluate the degree of cardiac hypertrophy, respectively. GLUT1, GLUT4, and IR were detected to assess cardiac glucose metabolism. Cardiac function was determined by echocardiography. Then, glucose oxidation and uptake, glycolysis and fatty acid metabolism were assessed in Langendorff perfusion of hearts. Finally, PI3K/AKT activator was used to further explore the relevant mechanism. The results showed that during cardiac pressure overload, with the aggravation of cardiac hypertrophy and dysfunction, cardiac glucose metabolism and glycolysis increased, and fatty acid metabolism decreased. After SH2B1-siRNA transfection, cardiac SH2B1 expression was knocked down, and the degree of cardiac hypertrophy and dysfunction was alleviated compared with the Control-siRNA transfected group. Simultaneously, cardiac glucose metabolism and glycolysis were reduced, and fatty acid metabolism was enhanced. The SH2B1 expression knockdown mitigated the cardiac hypertrophy and dysfunction by reducing cardiac glucose metabolism. After using PI3K/AKT activator, the effect of SH2B1 expression knockdown on cardiac glucose metabolism was reversed during cardiac hypertrophy and dysfunction. Collectively, SH2B1 regulated cardiac glucose metabolism by activating the PI3K/AKT pathway during pressure overload-induced cardiac hypertrophy and cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied Pressure overload-induced cardiac hypertrophy and dysfunction. SH2B1-siRNA vs. Control-siRNA was evaluated on Cardiac hypertrophy, dysfunction, and glucose metabolism. SH2B1 knockdown via siRNA mitigated pressure overload-induced cardiac hypertrophy and dysfunction by reducing cardiac glucose metabolism through the PI3K/AKT pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: